Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2023 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
June 20, 2023 08:00 ET | Source: BeyondSpring, Inc.

SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the...
June 07, 2023 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
May 18, 2023 08:30 ET | Source: BeyondSpring, Inc.

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking...
April 18, 2023 16:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

- SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration - BeyondSpring Completed Enrollment of Three Investigator-Initiated Trials (IIT) with Plinabulin...
April 18, 2023 16:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Files 2022 Annual Report on Form 20-F

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical-stage global biopharmaceutical company focused on using its novel...
March 01, 2023 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative...
January 09, 2023 16:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative...
December 13, 2022 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving...
November 23, 2022 16:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative...